Caxton Associates (New York)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,027	Closed	-$389K	–	627
2023 Q2	$389K	Buy	20,027 +1,414	+8%	+$27.5K	0.06%	305
2023 Q1	$528K	Buy	+18,613	New	+$528K	0.08%	245
2020 Q2	–	Sell	-4,571	Closed	-$210K	–	648
2020 Q1	$210K	Buy	+4,571	New	+$210K	0.04%	334